Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2016

Open Access 01-12-2016 | Research

Ulinastatin administration is associated with a lower incidence of acute kidney injury after cardiac surgery: a propensity score matched study

Authors: Xin Wan, Xiangcheng Xie, Yasser Gendoo, Xin Chen, Xiaobing Ji, Changchun Cao

Published in: Critical Care | Issue 1/2016

Login to get access

Abstract

Background

Systemic inflammation is involved in the development of acute kidney injury (AKI) after cardiac surgery with cardiopulmonary bypass (CPB). Ulinastatin, a urinary trypsin inhibitor (UTI), possesses a variety of anti-inflammatory effects. Therefore, we hypothesized that the administration of ulinastatin would reduce the occurrence of AKI in patients undergoing cardiac surgery with CPB.

Methods

A retrospective propensity score matched analysis was used to evaluate the effect of ulinastatin on the development of AKI in patients undergoing first documented cardiac surgery with CPB between January 2008 and December 2012 in our hospital. Multiple logistic regression models were also employed to identify the association between UTI administration and development of AKI.

Results

A total of 2072 patients who underwent cardiac surgery with CPB met the inclusion criteria. Before propensity score matching, variables such as age, baseline creatinine, CPB duration, red blood cells transfused, and hematocrit were statistically different between the ulinastatin (UTI) group and the control group. On the basis of propensity scores, 409 UTI patients were successfully matched to the 409 patients from among those 1663 patients without UTI administration. After propensity score matching, no statistically significant differences in the baseline characteristics were found between the UTI group and the control group. The propensity score matched cohort analysis revealed that AKI and the need for renal replacement therapy occurred more frequently in the control group than in the UTI group (40.83 % vs. 30.32 %, P = 0.002; 2.44 % vs. 0.49 %, P = 0.02, respectively). However, there were no significant differences in mortality, length of intensive care unit stay, and length of hospital stay between the UTI group and the control group. Using multivariate logistic regression analysis, we found ulinastatin played a protective role in the development of AKI after cardiac surgery (odds ratio 0.71, 95 % confidence interval 0.56–0.90, P = 0.005).

Conclusions

This study shows that ulinastatin was associated with a lower incidence of AKI after cardiac surgery, suggesting that the administration of ulinastatin may be favorable for those patients undergoing cardiac surgery with CPB.
Literature
1.
Garg AX, Devereaux PJ, Yusuf S, Cuerden MS, Parikh CR, Coca SG, et al. Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial. JAMA. 2014;311(21):2191–8.CrossRefPubMed
2.
Parolari A, Pesce LL, Pacini D, Mazzanti V, Salis S, Sciacovelli C, et al. Risk factors for perioperative acute kidney injury after adult cardiac surgery: role of perioperative management. Ann Thorac Surg. 2012;93(2):584–91.CrossRefPubMed
3.
Brown JR, Kramer RS, Coca SG, Parikh CR. Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg. 2010;90(4):1142–8.CrossRefPubMed
4.
Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant. 1999;14(5):1158–62.CrossRefPubMed
5.
Robert AM, Kramer RS, Dacey LJ, Charlesworth DC, Leavitt BJ, Helm RE, et al. Cardiac surgery-associated acute kidney injury: a comparison of two consensus criteria. Ann Thorac Surg. 2010;90(6):1939–43.CrossRefPubMed
6.
Elmistekawy E, McDonald B, Hudson C, Ruel M, Mesana T, Chan V, et al. Clinical impact of mild acute kidney injury after cardiac surgery. Ann Thorac Surg. 2014;98(3):815–22.CrossRefPubMed
7.
Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol. 2004;15(6):1597–605.CrossRefPubMed
8.
Kolli H, Rajagopalam S, Patel N, Ranjan R, Venuto R, Lohr J, et al. Mild acute kidney injury is associated with increased mortality after cardiac surgery in patients with eGFR < 60 ml/min/1.73 m2. Ren Fail. 2010;32(9):1066–72.CrossRefPubMed
9.
Mao H, Katz N, Ariyanon W, Blanca-Martos L, Adýbelli Z, Giuliani A, et al. Cardiac surgery-associated acute kidney injury. Blood Purif. 2014;37 Suppl 2:34–50.CrossRefPubMed
10.
Vives M, Wijeysundera D, Marczin N, Monedero P, Rao V. Cardiac surgery-associated acute kidney injury. Interact Cardiovasc Thorac Surg. 2014;18(5):637–45.CrossRefPubMed
11.
Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1(1):19–32.CrossRefPubMed
12.
Greenberg JH, Whitlock R, Zhang WR, Thiessen-Philbrook HR, Zappitelli M, Devarajan P, et al. Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. Pediatr Nephrol. 2015;30(9):1519–27.CrossRefPubMed
13.
Gueret G, Lion F, Guriec N, Arvieux J, Dovergne A, Guennegan C, et al. Acute renal dysfunction after cardiac surgery with cardiopulmonary bypass is associated with plasmatic IL6 increase. Cytokine. 2009;45(2):92–8.CrossRefPubMed
14.
Scrascia G, Guida P, Rotunno C, de Luca Tupputi Schinosa L, Paparella D. Anti-inflammatory strategies to reduce acute kidney injury in cardiac surgery patients: a meta-analysis of randomized controlled trials. Artif Organs. 2014;38(2):101–12.CrossRefPubMed
15.
McBride WT, Prasad PS, Armstrong M, Patterson C, Gilliland H, Drain A, et al. Cytokine phenotype, genotype, and renal outcomes at cardiac surgery. Cytokine. 2013;61(1):275–84.CrossRefPubMed
16.
Thiele RH, Isbell JM, Rosner MH. AKI associated with cardiac surgery. Clin J Am Soc Nephrol. 2015;10(3):500–14.CrossRefPubMed
17.
Jeong CW, Lee CS, Lee SH, Jeung HJ, Kwak SH. Urinary trypsin inhibitor attenuates liver enzyme elevation after liver resection. Korean J Anesthesiol. 2012;63(2):120–3.CrossRefPubMedPubMedCentral
18.
Kim NY, Shim JK, Bang SO, Sim JS, Song JW, Kwak YL. Effects of ulinastatin on coagulation in high-risk patients undergoing off-pump coronary artery bypass graft surgery. Korean J Anesthesiol. 2013;64(2):105–11.CrossRefPubMedPubMedCentral
19.
Zhang ZF, Yang N, Zhao G, Zhu L, Zhu Y, Wang LX. Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis. Chin Med J (Engl). 2010;123(18):2600–6.
20.
Chen TT, Jiandong-Liu, Wang G, Jiang SL, Li LB, Gao CQ. Combined treatment of ulinastatin and tranexamic acid provides beneficial effects by inhibiting inflammatory and fibrinolytic response in patients undergoing heart valve replacement surgery. Heart Surg Forum. 2013;16(1):E38–47.CrossRefPubMed
21.
Zhang Y, Zeng Z, Cao Y, Du X, Wan Z. Effect of urinary protease inhibitor (ulinastatin) on cardiopulmonary bypass: a meta-analysis for China and Japan. PLoS One. 2014;9(12):e113973.CrossRefPubMedPubMedCentral
22.
Lesperance R, Lehman R, Lesperance K, Cronk D, Martin M. Early postoperative fever and the “routine” fever work-up: results of a prospective study. J Surg Res. 2011;171(1):245–50.CrossRefPubMed
23.
Corral-Velez V, Lopez-Delgado JC, Betancur-Zambrano NL, Lopez-Suñe N, Rojas-Lora M, Torrado H, et al. The inflammatory response in cardiac surgery: an overview of the pathophysiology and clinical implications. Inflamm Allergy Drug Targets. 2015;13(6):367–70.CrossRefPubMed
24.
25.
Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002;62(5):1539–49.CrossRefPubMed
26.
Jongman RM, Zijlstra JG, Kok WF, van Harten AE, Mariani MA, Moser J, et al. Off-pump CABG surgery reduces systemic inflammation compared with on-pump surgery but does not change systemic endothelial responses: a prospective randomized study. Shock. 2014;42(2):121–8.CrossRefPubMed
27.
Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg. 1996;61(6):1714–20.CrossRefPubMed
28.
Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002;21(2):232–44.CrossRefPubMed
29.
Kraft F, Schmidt C, Van Aken H, Zarbock A. Inflammatory response and extracorporeal circulation. Best Pract Res Clin Anaesthesiol. 2015;29(2):113–23.CrossRefPubMed
30.
Heyn J, Beiras-Fernandez A, Luchting B, Briegel J, Weis F. Inflammatory reactions and hydrocortisone in the setting of cardiac surgery: an overview. Cardiovasc Hematol Agents Med Chem. 2011;9(1):56–61.CrossRefPubMed
31.
Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose–response meta-analysis. Circulation. 2009;119(14):1853–66.CrossRefPubMed
32.
Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA. 2012;308(17):1761–7.CrossRefPubMed
33.
Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM, Paparella D. Protective effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J Cardiothorac Vasc Anesth. 2011;25(1):156–65.CrossRefPubMed
34.
Inoue K, Takano H, Shimada A, Yanagisawa R, Sakurai M, Yoshino S, et al. Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol. 2005;67(3):673–80.CrossRefPubMed
35.
Shu H, Liu K, He Q, Zhong F, Yang L, Li Q, et al. Ulinastatin, a protease inhibitor, may inhibit allogeneic blood transfusion-associated pro-inflammatory cytokines and systemic inflammatory response syndrome and improve postoperative recovery. Blood Transfus. 2014;12 Suppl 1:s109–18.PubMedPubMedCentral
36.
Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock. 2001;15(2):101–5.CrossRefPubMed
37.
Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol. 2001;69(2):241–7.PubMed
38.
Gao C, Huan J, Li W, Tang J. Protective effects of ulinastatin on pancreatic and renal damage in rats following early scald injury. Burns. 2009;35(4):547–52.CrossRefPubMed
39.
Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, et al. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014;40(6):830–8.CrossRefPubMedPubMedCentral
40.
Park KH, Lee KH, Kim H, Hwang SO. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci. 2010;25(1):128–34.CrossRefPubMed
41.
Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation. 2011;124(25):2822–8.CrossRefPubMed
42.
Song J, Park J, Kim JY, Kim JD, Kang WS, Muhammad HB, et al. Effect of ulinastatin on perioperative organ function and systemic inflammatory reaction during cardiac surgery: a randomized double-blinded study. Korean J Anesthesiol. 2013;64(4):334–40.CrossRefPubMedPubMedCentral
43.
Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med. 2006;34(5):1351–7.CrossRefPubMed
44.
He S, Lin K, Ma R, Xu R, Xiao Y. Effect of the urinary tryptin inhibitor ulinastatin on cardiopulmonary bypass-related inflammatory response and clinical outcomes: a meta-analysis of randomized controlled trials. Clin Ther. 2015;37(3):643–53.CrossRefPubMed
45.
Oh SY, Kim JC, Choi YS, Lee WK, Lee YK, Kwak YL. Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass. Korean J Anesthesiol. 2012;62(2):148–53.CrossRefPubMedPubMedCentral
46.
Lema G. Ulinastatin treatment and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass: a note of caution. Korean J Anesthesiol. 2013;64(1):91–2.CrossRefPubMedPubMedCentral
Metadata
Title
Ulinastatin administration is associated with a lower incidence of acute kidney injury after cardiac surgery: a propensity score matched study
Authors
Xin Wan
Xiangcheng Xie
Yasser Gendoo
Xin Chen
Xiaobing Ji
Changchun Cao
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2016
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-016-1207-7

Other articles of this Issue 1/2016

Critical Care 1/2016 Go to the issue

Research

The involvement of regulatory non-coding RNAs in sepsis: a systematic review

Research

Unexpected versus all-cause mortality as the endpoint for investigating the effects of a Rapid Response System in hospitalized patients

Research

Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review

Erratum

Erratum to: A prospective multicenter cohort study of frailty in younger critically ill patients

Research

A novel cardiovascular risk stratification model incorporating ECG and heart rate variability for patients presenting to the emergency department with chest pain

Review

Optimizing sedation in patients with acute brain injury